Does the yield of prostate cancer biopsy and repeat biopsy justify the frequency of their use?
Joseph Presti Jr
Correspondence Department of Urology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2217, Stanford, CA 94305-5826, USA
This article has no abstract so we have provided the first paragraph of the full text.
This observational study addresses a couple of simple questions. Firstly, what is the yield of a prostate needle biopsy in the PSA era? Secondly, what is the cumulative risk of prostate cancer detection in patients who undergo repeat biopsies? The authors attempt to answer these questions using a Medicare–SEER dataset.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.